Anti-MLH1 antibody (ab47703)

Overview

• Product nameAnti-MLH1 antibodySee all MLH1 primary antibodies ...
• Description
  Rabbit polyclonal to MLH1
• Tested applicationsWB, ICC/IF more details
• Species reactivity
  Reacts with: Mouse, Rat, Human
  Predicted to work with: Horse, Cow, Dog, Chimpanzee, Zebra finch
• Immunogen

  Synthetic peptide conjugated to KLH derived from within residues 700 to the C-terminus of Human MLH1.

  Read Abcam's proprietary immunogen policy

  (Peptide available as ab86630.)

• Positive controlThis antibody gave a positive signal in the following lysates: U2OS Whole Cell; Human Thymus Tissue; Mouse Spleen Tissue; Rat Spleen Tissue.

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: 1% BSA, PBS, pH 7.4
• Concentration information loading...
• PurityImmunogen affinity purified
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Cancer
  • Oncoproteins/suppressors
  • Tumor suppressors
  • Other

  • Epigenetics and Nuclear Signaling
  • DNA / RNA
  • DNA Damage & Repair
  • Mismatch Repair

Applications

Target

• FunctionHeterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
• Tissue specificityColon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
• Involvement in diseaseDefects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
  Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
  Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
  Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
  Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
  Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.
• Sequence similaritiesBelongs to the DNA mismatch repair mutL/hexB family.
• Cellular localizationNucleus.

Target information above from: UniProt accession P40692 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 4292 Human
  • Entrez Gene: 17350 Mouse
  • Entrez Gene: 81685 Rat
  • Omim: 120436 Human
  • SwissProt: P40692 Human
  • SwissProt: Q9JK91 Mouse
  • SwissProt: P97679 Rat
  • Unigene: 195364 Human

  • Unigene: 196006 Mouse
  • Unigene: 20391 Rat

  see all

• Alternative names
  COCA 2 antibodyCOCA2 antibodyDNA mismatch repair protein Mlh1 antibody

  FCC 2 antibodyFCC2 antibodyhMLH 1 antibodyhMLH1 antibodyHNPCC 2 antibodyHNPCC antibodyHNPCC2 antibodyMGC5172 antibodyMLH 1 antibodyMLH1 antibodyMLH1_HUMAN antibodyMutL homolog 1 (E. coli) antibodyMutL homolog 1 antibodyMutL homolog 1 colon cancer nonpolyposis type 2 antibodyMutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibodyMutL protein homolog 1 antibodyMutL, E. coli, homolog of, 1 antibody

  see all

Anti-MLH1 antibody images

• 

  Western blot - MLH1 antibody (ab47703)
  All lanes : Anti-MLH1 antibody (ab47703) at 1 µg/ml
  
  Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
  Lane 2 : Thymus (Human) Tissue Lysate - adult normal tissue (ab30146)
  
  Lysates/proteins at 10 µg per lane.
  
  Secondary
  Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 85 kDa
  Observed band size : 85 kDa
  Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.
• 

  Immunocytochemistry/ Immunofluorescence - MLH1 antibody (ab47703)
  ICC/IF image of ab47703 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab47703, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 5µg/ml.
• 

  Western blot - Anti-MLH1 antibody (ab47703)
  All lanes : Anti-MLH1 antibody (ab47703) at 1 µg/ml
  
  Lane 1 : Spleen (Mouse) Tissue Lysate
  Lane 2 : Spleen (Rat) Tissue Lysate
  
  Lysates/proteins at 10 µg per lane.
  
  Secondary
  Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) (ab65484) at 1/5000 dilution
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 85 kDa
  Observed band size : 85 kDa
  
  
  Exposure time : 20 minutes